Metronomic chemotherapy in pediatric neuroblastoma

Abstract

Metronomic chemotherapy (MC) is an innovative therapeutic approach that involves the chronic administration of low doses of chemotherapy agents. This strategy aims to sustain prolonged and active plasma levels of drugs, which can result in favorable tolerability. MC has shown promise in the treatment of hematologic and solid tumors, including high-risk neuroblastoma and relapsed/refractory (R/R) neuroblastoma. In the contemporary management of neuroblastoma, MC stands as a viable maintenance therapy for newly diagnosed patients lacking access to autologous stem cell transplantation or immunotherapy, particularly in resource-constrained regions. Furthermore, it serves as a pragmatic alternative for individuals intolerant to intensified regimens or undergoing palliative care for R/R neuroblastoma. Nevertheless, the quest for the optimal MC regimen persists, necessitating comprehensive investigations to delineate standardized protocols. Moreover, the identification of potential biomarkers or prognostic indicators assumes paramount significance in refining MC strategies for future breakthroughs in this domain. This review embarks on a comprehensive exploration of MC in neuroblastoma, offering insights into its historical underpinnings, diverse applications, adverse effect and future prospects, endeavoring to enrich our understanding of MC role in neuroblastoma management.

Keywords

clinical trial and review / metronomic therapy / neuroblastoma / pediatric

References

[1] KerbelRS, KamenBA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4(6):423-436.

[2] HanahanD, Bergers G, BergslandE. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000; 105(8):1045-1047.

[3] CazzanigaME, Camerini A, AddeoR, et al. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. Future Oncol. 2016; 12(3):373-387.

[4] AndréN, Carré M, PasquierE. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014; 11(7):413-431.

[5] ColleoniM, GrayKP, GelberS, et al. Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: international breast cancer study group trial 22-00. J Clin Oncol. 2016; 34(28):3400-3408.

[6] KerbelRS, ShakedY. The potential clinical promise of ‘multimodality’ metronomic chemotherapy revealed by preclinical studies of metastatic disease. Cancer Lett. 2017; 400:293-304.

[7] KarevaI, WaxmanDJ, Lakka KlementG. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015; 358(2):100-106.

[8] BocciG, KerbelRS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016; 13(11):659-673.

[9] GnoniA, Silvestris N, LicchettaA, et al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol. 2015; 95(1):46-61.

[10] BaruchelS, DieziM, HargraveD, et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer. 2006; 42(14):2335-2342.

[11] SterbaJ, Pavelka Z, SlampaP. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma. 2002; 49(2):117-120.

[12] KieranMW, TurnerCD, RubinJB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005; 27(11):573-581.

[13] StempakD, GammonJ, HaltonJ, Moghrabi A, KorenG, BaruchelS. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol. 2006; 28(11):720-728.

[14] SterbaJ, ValikD, MudryP, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie. 2006; 29(7):308-313.

[15] WhittleSB, SmithV, DohertyE, Zhao S.-B, McCartyS, ZagePE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017; 17(4):369-386.

[16] LondonWB, Bagatell R, WeigelBJ, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017; 123(24):4914-4923.

[17] KushnerBH, KramerK, CheungNK. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol. 1999; 17(10):3221-3225.

[18] AndréN, AbedS, OrbachD, et al. Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget. 2011; 2(12):960-965.

[19] RussellHV, Groshen SG, AraT, et al. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011; 57(2):275-282.

[20] Minard-ColinV, Ichante JL, NguyenL, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma: a report from the Société Française des Cancers et leucémies de l’Enfant et de l’adolescent (SFCE). Eur J Cancer. 2012; 48(15):2409-2416.

[21] TraoreF, TogoB, PasquierE, Dembélé A, AndréN. Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02. Indian J Cancer. 2013; 50(3):250-253.

[22] ZapletalovaD, André N, DeakL, et al. Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology. 2012; 82(5):249-260.

[23] RobisonNJ, Campigotto F, ChiSN, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014; 61(4):636-642.

[24] PramanikR, Agarwala S, GuptaYK, et al. Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors: a randomized clinical trial. JAMA Oncol. 2017; 3(9):1222-1227.

[25] AliAM, El-Sayed MI. Metronomic chemotherapy and radiotherapy as salvage treatment in refractory or relapsed pediatric solid tumours. Curr Oncol. 2016; 23(3): e253-e259.

[26] El KababriM, Benmiloud S, CherkaouiS, et al. Metro-SMHOP 01: metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies. Pediatr Blood Cancer. 2020; 67(9):e28508.

[27] FousseyniT, Diawara M, PasquierE, AndréN. Children treated with metronomic chemotherapy in a low-income country: METRO-Mali-01. J Pediatr Hematol Oncol. 2011; 33(1):31-34.

[28] Heng-MaillardMA, Verschuur A, AscheroA, et al. SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor. Pediatr Blood Cancer. 2019; 66(7):e27693.

[29] SunX.-F, ZhenZ.-J, GuoY, et al. Oral metronomic maintenance therapy can improve survival in high-risk neuroblastoma patients not treated with ASCT or anti-GD2 antibodies. Cancers. 2021; 13(14):3494.

[30] D’AmicoS, Tempora P, GrageraP, et al. Two bullets in the Gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity. Front Immunol. 2023; 14:1268645.

[31] WebbER, Moreno-Vincente J, EastonA, et al. Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma. iScience. 2022; 25(9):104995.

[32] ManjiA, SamsonY, DeyellRJ, et al. Low-dose metronomic topotecan and pazopanib (TOPAZ) in children with relapsed or refractory solid tumors: a C17 Canadian phase I clinical trial. Cancers. 2022; 14(12):2985.

[33] BertholdF, BoosJ, BurdachS, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005; 6(9):649-658.

[34] SimonT, HeroB, FaldumA, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer. 2011; 11(1):21.

[35] BagatellR, DuBoisSG, NaranjoA, et al. Children’s Oncology Group’s 2023 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2023; 70(suppl 6):e30572.

[36] ParkJR, Kreissman SG, LondonWB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019; 322(8):746-755.

[37] YuAL, GilmanAL, OzkaynakMF, et al. Long-term follow-up of a phase III study of ch14.18 (dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clin Cancer Res. 2021; 27(8):2179-2189.

[38] BrowderT, Butterfield CE, KrälingBM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000; 60(7):1878-1886.

[39] WaetzigR, Matthes M, LeisterJ, et al. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells. Int J Med Sci. 2021; 18(1):137-149.

[40] ZhangL.-B, WuB, BaruchelS. Oral metronomic topotecan sensitizes crizotinib antitumor activity in ALK^F1174L drug-resistant neuroblastoma preclinical models. Transl Oncol. 2017; 10(4):604-611.

[41] MorenoL, RubieH, VaroA, et al. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr Blood Cancer. 2017; 64(1):25-31.

[42] ModyR, Naranjo A, Van RynC, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221):an open-label, randomised, phase 2 trial. Lancet Oncol. 2017; 18(7):946-957.

[43] OesterheldJ, Ferguson W, KravekaJM, et al. Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons. J Clin Oncol. 2024; 42(1):90-102.

[44] BertholdF, Hömberg M, ProleskovskayaI, et al. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. Pediatr Hematol Oncol. 2017; 34(5):308-319.

[45] PasqualiniC, RubinoJ, BrardC, et al. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children with Cancer Consortium. Eur J Cancer. 2021; 150:53-62.

[46] CarcamoB, Francia G. Cyclic metronomic chemotherapy for pediatric tumors: six case reports and a review of the literature. J Clin Med. 2022; 11(10):2849.

[47] ParikhNS, HowardSC, ChantadaG, et al. SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015; 62(8):1305-1316.

[48] Revon-RivièreG, Banavali S, HeississenL, et al. Metronomic chemotherapy for children in low- and middle-income countries: survey of current practices and opinions of pediatric oncologists. J Glob Oncol. 2019; 5:1-8.

[49] PramanikR, Bakhshi S. Metronomic therapy in pediatric oncology: a snapshot. Pediatr Blood Cancer. 2019; 66(9):e27811.

[50] PorkholmM, Toiviainen-Salo S, SeuriR, et al. Metronomic therapy can increase quality of life during paediatric palliative cancer care, but careful patient selection is essential. Acta Paediatr. 2016; 105(8):946-951.

[51] BalkinEM, Thompson D, ColsonKE, LamCG, Matthay KK. Physician perspectives on palliative care for children with neuroblastoma: an international context. Pediatr Blood Cancer. 2016; 63(5):872-879.

[52] Le DeleyMC, VassalG, TaïbiA, Shamsaldin A, LeblancT, HartmannO. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer. 2005; 45(1):25-31.

[53] De VitaS, De Matteis S, LaurentiL, et al. Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol. 2005; 84(11):760-762.

[54] TohYM, LiTK. Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway. Clin Cancer Res. 2011; 17(15):5026-5037.

[55] ZhangL, HouY.-H, LiN, WuK, ZhaiJ.-S. The influence of TXNDC5 gene on gastric cancer cell. J Cancer Res Clin Oncol. 2010; 136(10):1497-1505.

[56] VoKT, KarskiEE, NasholmNM, et al. Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget. 2017; 8(14):23851-23861.

[57] AndreN, CointeS, BarlogisV, et al. Maintenance chemotherapy in children with ALL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect. Oncotarget. 2015; 6(26):23008-23014.

RIGHTS & PERMISSIONS

2024 The Author(s). Pediatric Discovery published by John Wiley & Sons Australia, Ltd on behalf of Children’s Hospital of Chongqing Medical University.